Teva Reports Positive Phase 1b Results for Vitiligo Antibody, Plans Phase 2b in 2026
Translated & summarized from Globes by baba
Teva announced positive Phase 1b results for TEV-408, an antibody for vitiligo treatment, showing significant skin pigmentation improvement and safety. The company plans to start Phase 2b trials by late 2026, supported by a funding deal with Royalty Pharma.
The story in 6 lines · by baba
- Teva's TEV-408 antibody shows significant skin pigmentation improvement in Phase 1b vitiligo trial.
- About 75% of patients reported facial vitiligo improvement; 55% saw body-wide benefits.
- TEV-408 is administered subcutaneously every 12 weeks with a positive safety profile.
- Teva plans to begin Phase 2b trials in Q4 2026 for TEV-408.
- Royalty Pharma agreed to fund up to $925 million for TEV-408's development stages.
- Teva will pay royalties to Royalty Pharma on international sales if the drug is approved.
Teva Pharmaceutical Industries announced encouraging results from its ongoing Phase 1b study of TEV-408, an antibody developed to treat vitiligo, a chronic skin condition. The antibody is administered subcutaneously every 12 weeks and demonstrated improved skin pigmentation in patients with non-segmental vitiligo, along with a favorable safety profile and no new safety signals. Approximately 75% of patients reported facial vitiligo improvement, with half describing significant or very significant progress, and 55% noted improvement across the entire body.
Richard Francis, Teva's President and CEO, highlighted TEV-408 as a key example of the company's innovative immunology pipeline, emphasizing its commitment to addressing unmet medical needs and returning to growth. Dr. Eric Hughes, Senior Vice President and Chief Medical Officer, stressed the broader impact of vitiligo on patients' self-perception and confidence, expressing optimism about the IL-15 pathway targeted by TEV-408 and its potential to offer a meaningful treatment alternative.
Earlier this year, Teva entered a partnership with Royalty Pharma to accelerate the drug's development. The agreement includes up to $500 million in funding from Royalty Pharma for ongoing development costs, with an option for an additional $425 million to support Phase 3 trials based on Phase 2b results. If successful and approved, Teva will pay royalties to Royalty Pharma on international sales of the medication. Teva plans to advance TEV-408 to Phase 2b trials in the fourth quarter of 2026.